» Articles » PMID: 23166327

Oncogenic MicroRNA-155 Down-regulates Tumor Suppressor CDC73 and Promotes Oral Squamous Cell Carcinoma Cell Proliferation: Implications for Cancer Therapeutics

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2012 Nov 21
PMID 23166327
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

The CDC73 gene is mutationally inactivated in hereditary and sporadic parathyroid tumors. It negatively regulates β-catenin, cyclin D1, and c-MYC. Down-regulation of CDC73 has been reported in breast, renal, and gastric carcinomas. However, the reports regarding the role of CDC73 in oral squamous cell carcinoma (OSCC) are lacking. In this study we show that CDC73 is down-regulated in a majority of OSCC samples. We further show that oncogenic microRNA-155 (miR-155) negatively regulates CDC73 expression. Our experiments show that the dramatic up-regulation of miR-155 is an exclusive mechanism for down-regulation of CDC73 in a panel of human cell lines and a subset of OSCC patient samples in the absence of loss of heterozygosity, mutations, and promoter methylation. Ectopic expression of miR-155 in HEK293 cells dramatically reduced CDC73 levels, enhanced cell viability, and decreased apoptosis. Conversely, the delivery of a miR-155 antagonist (antagomir-155) to KB cells overexpressing miR-155 resulted in increased CDC73 levels, decreased cell viability, increased apoptosis, and marked regression of xenografts in nude mice. Cotransfection of miR-155 with CDC73 in HEK293 cells abrogated its pro-oncogenic effect. Reduced cell proliferation and increased apoptosis of KB cells were dependent on the presence or absence of the 3'-UTR in CDC73. In summary, knockdown of CDC73 expression due to overexpression of miR-155 not only adds a novelty to the list of mechanisms responsible for its down-regulation in different tumors, but the restoration of CDC73 levels by the use of antagomir-155 may also have an important role in therapeutic intervention of cancers, including OSCC.

Citing Articles

Development of morphologically diverse benign neoplasms preceding metachronous oral squamous cell carcinoma: A rare case report.

Padhiary S, Srivastava G, Panda S, Mohanty N Natl J Maxillofac Surg. 2025; 15(3):521-525.

PMID: 39830462 PMC: 11737561. DOI: 10.4103/njms.njms_135_23.


miR-198 targets : implications for oral squamous cell carcinoma pathogenesis.

Kaushik P, Mishra R, Gopal C, Kumar A Front Oncol. 2024; 14:1485802.

PMID: 39697236 PMC: 11652479. DOI: 10.3389/fonc.2024.1485802.


miR-617 interacts with the promoter of and positively regulates its expression: implications for cancer therapeutics.

Sarkar N, Mishra R, Gopal C, Kumar A Front Oncol. 2024; 14:1411539.

PMID: 38939334 PMC: 11208480. DOI: 10.3389/fonc.2024.1411539.


Intronic miR-6741-3p targets the oncogene SRSF3: Implications for oral squamous cell carcinoma pathogenesis.

More D, Singh N, Mishra R, Muralidharan H, Gopinath K, Gopal C PLoS One. 2024; 19(5):e0296565.

PMID: 38781195 PMC: 11115324. DOI: 10.1371/journal.pone.0296565.


CDC73 serves as a tumour-promoting factor in oesophageal cancer.

Song J, Guo W, Xu H, Gao T Heliyon. 2024; 10(9):e29904.

PMID: 38707440 PMC: 11066309. DOI: 10.1016/j.heliyon.2024.e29904.


References
1.
Pimenta F, Silveira L, Tavares G, Silva A, Perdigao P, Castro W . HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncol. 2006; 42(7):735-9. DOI: 10.1016/j.oraloncology.2005.11.019. View

2.
Zhang W, Dahlberg J, Tam W . MicroRNAs in tumorigenesis: a primer. Am J Pathol. 2007; 171(3):728-38. PMC: 1959494. DOI: 10.2353/ajpath.2007.070070. View

3.
Kong W, Yang H, He L, Zhao J, Coppola D, Dalton W . MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008; 28(22):6773-84. PMC: 2573297. DOI: 10.1128/MCB.00941-08. View

4.
Chakraborty S, Azeem Mohiyuddin S, Gopinath K, Kumar A . Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 2008; 8:163. PMC: 2430211. DOI: 10.1186/1471-2407-8-163. View

5.
Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L . Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004; 89(11):5583-91. DOI: 10.1210/jc.2004-0294. View